Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

Gan & Lee Pharmaceuticals (SHSE: 603087) has successfully administered the first dose of its biosimilar drug, GLR1023 injection (proposed as a biosimilar to Secukinumab), in a Phase 1 clinical study targeting moderate to severe plaque psoriasis in healthy participants in China. This randomized, blinded, single-dose, positive control trial aims to evaluate the pharmacokinetic parameters, immunogenicity, and safety of GLR1023 compared to the reference product, Secukinumab, in healthy adult males. Psoriasis is a chronic, immune-mediated, and recurrent skin disease that can last for decades and affect the physical and mental health of patients. Following the data released by the National Psoriasis Foundation (NPF), it is estimated that 125 million people worldwide have psoriasis. The global prevalence of psoriasis is 2 to 3 percent of the total population and can develop at any age in both males and females. According to data, the global sales of Secukinumab reached $4.788 billion in 2022. #Biosimilars #ClinicalTrials #Psoriasis #Innovation #Healthcare #Pharmaceuticals #QimingPortfolio #QimingHealthcare

Asieris Pharmaceuticals (SHSE: 688176) announced that the US FDA has approved the Investigational New Drug (IND) application for APL-2302, a ubiquitin-specific protease 1 (USP1) inhibitor, for the treatment of advanced solid tumors. APL-2302 is a novel USP1 inhibitor with fully independent intellectual property rights, functioning via a "synthetic lethality" mechanism. Non-clinical pharmacodynamics (PD) studies show that APL-2302 is an active USP1 inhibitor, demonstrating excellent tumor suppression efficacy in vitro and in vivo, both as a monotherapy and in combination therapies. It offers promising potential as a new treatment option for patients with advanced solid tumors, including those with breast, ovarian, prostate, and other solid tumors characterized by specific biomarkers, such as BRCA mutations. #FDAApproval #INDApplication #APL2302 #USP1Inhibitor #CancerResearch #SolidTumors #SyntheticLethality #CancerInnovation #PharmaNews #Oncology #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gpk-nmW9

The Bayer China Center of Innovation and Partnership (CCIP) has officially opened in Shanghai. As part of this initiative, our portfolio company Wecare Probiotics Co., Ltd., specializing in probiotic strain research, production, and application, has joined as a key partner. Wecare Probiotics will collaborate with Bayer to drive advancements in the probiotics sector. This partnership will focus on technological innovation, industry integration, and resource sharing to enhance research and product development in this field. Together, they aim to achieve greater synergy and drive breakthroughs in health consumer products, ultimately delivering high-quality probiotic solutions to consumers across China. #Probiotics #HealthInnovation #Bayer #ConsumerHealth #Collaboration #QualityHealthProducts #QimingPortfolio #QimingConsumer

A multi-center study led by Prof. Longjiang Zhang's team at Jinling Hospital, affiliated with the Medical School of Nanjing University, with support from our portfolio company Shukun Technology, was recently published in the prestigious journal Radiology. This study highlights how Shukun Technology's CT-FFR is transforming CAD diagnostic pathways. The randomized controlled trial involved 5,297 cases, comparing outcomes between a CCTA+CT-FFR group and a CCTA-only group. Findings showed a 19.4% reduction in 90-day ICA incidence when CT-FFR was combined with CCTA. By serving as an effective "gatekeeper" for ICA, Shukun Technology enhances diagnostic accuracy for clinicians, reduces invasive procedures for patients, and helps manage healthcare costs. #MedicalInnovation #Radiology #CoronaryArteryDisease #CTFFR #HealthcareTechnology #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/g6EcXvJR

RiboX Therapeutics announced that the US FDA has cleared its IND application for the Phase 1/2a Study of RXRG001 (SPRINX-1 Study) recently. RXRG001 is the first-ever circular RNA therapy to receive FDA IND clearance. This important advancement marks a significant milestone as circular RNA drugs advance into the clinical development phase. The FIH SPRINX-1 study is designed to evaluate the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) (dry mouth) and hyposalivation (low saliva secretion). RXRG001 is a proprietary product developed using innovative circular RNA technology. RXRG001 consists of the circular RNA coding human aquaporin 1 (hAQP1, a water channel protein of cell membrane), encapsulated in lipid nanoparticles (LNPs). RXRG001 increases saliva production by restoring water permeability via overexpression of hAQP1, therefore it alleviates dry mouth symptoms. Non-clinical studies demonstrated a favorable risk and benefit profile of RXRG001 in animal models. For instance, a single administration of RXRG001 led to a significant increased salivary flow which was sustained for about four weeks. #CircularRNATherapy #ClinicalTrials #FDAApproval #XerostomiaTreatment #SalivaRestoration #InnovativeTherapies #DryMouthRelief #BiotechBreakthrough #Aquaporin1 #LipidNanoparticles #RNAInnovation #SPRiNX1Study #PrecisionMedicine #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gU7JBJnv

Our portfolio company HyperStrong showcased its latest technological innovations and green energy solutions at All-Energy Australia 2024. During the event, HyperStrong signed several key partnership agreements with local companies, reinforcing its commitment to expanding in the APAC market. Among these new collaborations, HyperStrong partnered with Australia's Tesseract on a long-term project in large-scale, industrial, and commercial energy storage—a significant milestone following the recent establishment of its APAC headquarters in Sydney. Together, they will drive forward energy storage initiatives to support Australia's clean energy transition. HyperStrong also teamed up with local EMS leaders, including AZZO and PowerSync, further embedding itself in the regional energy management ecosystem. These partnerships position HyperStrong to deliver advanced energy storage solutions across the APAC region, addressing the area's growing energy demands. #EnergyStorage #GreenEnergy #CleanEnergy #AllEnergyAustralia #RenewableEnergy #AsiaPacific #EnergyInnovation #SustainableSolutions #EnergyTransition #QimingPortfolio #QimingTechnology

At Africa Health 2024, Pluslife unveiled a series of cutting-edge diagnostic products. Highlights included innovative molecular point-of-care testing (POCT) solutions for tuberculosis (TB) and human papillomavirus (HPV), purpose-built for primary healthcare facilities to transform and decentralize infectious disease diagnostics. A standout among the offerings is Pluslife's TB molecular POCT, which allows for dual-specimen testing (tongue swab/sputum) and combines high performance with affordability and rapid results. This innovation is particularly suited for resource-limited, decentralized healthcare settings, promoting a shift from reactive care to proactive screening and advancing efforts toward the WHO's 2035 TB eradication goal. #AfricaHealth2024 #HealthcareInnovation #PointOfCareTesting #InfectiousDisease #PrimaryCare #DecentralizedDiagnostics #MedicalTechnology #GlobalHealth #TBCare #Diagnostics #QimingPortfolio #QimingHealthcare

Zai Lab (NASDAQ: ZLAB, SEHK: 9688) presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Spain, as an oral presentation during the plenary session. ZL-1310 is being tested in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) after at least one prior platinum-based chemotherapy regimen. "The preliminary results from the ongoing Phase 1 trial of ZL-1310 suggest that this next-generation ADC therapy has the potential to deliver anti-tumor responses in the majority of patients with ES-SCLC, with good tolerability," said Dr. Alex Spira, a medical oncologist at Virginia Cancer Specialists and NEXT Oncology. "This is particularly encouraging given the urgent need for improved treatment options for these patients. These promising data support continued evaluation of ZL-1310 as a monotherapy in the dose-expansion phase of the ongoing Phase 1 clinical trial and in combination." #ZL1310 #SmallCellLungCancer #Phase1Trial #Oncology #ADC #CancerResearch #ENA2024 #ClinicalTrials #LungCancerTreatment #NextGenTherapies #AntibodyDrugConjugate #BiopharmaInnovation #CancerTreatment #PrecisionMedicine #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/g8MPWZiB

Congratulations to our portfolio company Hope Medicine Inc on the positive results from an interim analysis of a global Phase 2 study. This is a randomized, multicenter, double-blind, placebo-controlled study to evaluate the safety and efficacy of HMI-115 in women with moderate to severe endometriosis-associated pain over a 12-week treatment period. HMI-115 is a monoclonal antibody that blocks the prolactin receptor. It is a first-in-class treatment for endometriosis. Notably, HMI-115 has been granted Breakthrough Therapy Designation by China's NMPA. This Phase 2 study included 142 female patients with endometriosis in US, Poland and China. HMI-115 has demonstrated statistically significant improvement in endometriosis-associated pain. HMI-115 was well-tolerated with no treatment-related serious adverse events. "HMI-115 is first-in-class," said Professor Rui-Ping Xiao, Founder of Hope Medicine, "this study is the first ever to show that prolactin receptor blockade can treat patients suffering from endometriosis. For the last 40 years people have been calling for a new target that provides pain relief while bypassing sex hormones, we are answering that call." #HopeMedicine #Endometriosis #WomensHealth #ClinicalResearch #Phase2Results #HMI115 #BreakthroughTherapy #ProlactinReceptor #InnovativeMedicine #PainRelief #HealthcareInnovation #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/g39mA4r6